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PMACE (death, reinfarction, new onset heart failure, or rehospitalization for heart
failure): HR¼1.46 per 100 IU/L [1.23 to 1.73], p<0.001.O
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SConclusions: Peak CK-MB measurement is clinically useful to estimate infarct size
and LVEF as well as 1-year clinical outcomes after primary PCI for large anterior
STEMI.
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Background: The aim was to compare treatment and clinical outcomes of cardiogenic
shock (CS) AMI patients with and without severe renal dysfunction (SRD) on
admission.
Methods: We analyzed 676 patients with CS and AMI from PL-ACS registry.
Follow-up mortality was obtained from the government database.
Results: Patients with SRD comprised 16% of CS AMI pts. They were of higher risk
proﬁle and were less frequently treated invasively (table). Early and 2-year mortalities
are show in the table and ﬁgure.Severe renal
dysfunction
(GFR < 30)
N=106 (16%)
No severe renal
dysfunction
(GFR >= 30)
N=570 (84%) P value
Mean age, years  SD 76  9 67  12 <0.0001
Female sex, % 63 35 <0.0001
History of congestive heart
failure, %
19 10 0.0068
STEMI, % 64 76 0.0095
Primary PCI, % 39 66 <0.0001
Bypass surgery (CABG), % 1 3 0.31
Left ventricle ejection
fraction, %
31  11 37  13 0.0059
In-hospital major bleeding,
%
11 10 0.76
In-hospital stroke, % 1 2 0.76
In-hospital mortality, % 68 40 <0.0001
30-day mortality, % 80 49 <0.0001
2-year mortality, % 96 60 <0.0001
JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrConclusions: Invasive treatment reduces mortality in patients with cardiogenic shock
and severe renal dysfunction, however only less than 5% of SRD patients is alive after
2 years.
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Background: Cardiogenic shock (CS) complicating acute coronary syndromes is
associated with increased morbidity and mortality. Although percutaneous coronary
intervention (PCI) improves clinical outcomes, it is unclear whether drug eluting
stents (DES) are superior to bare metal stents (BMS) in reducing mortality in CS. In
this study we examined the effect of DES vs. BMS on mortality in patients with CS
undergoing PCI and whether DES use confers mortality beneﬁt speciﬁcally in ST-
elevation MI (STEMI) and/or non-ST elevation MI (NSTEMI).
Methods:We examined an observational cohort of 1024 patients with CS treated with
PCI between 2005 and 2011 at 8 tertiary cardiac centers across London, UK.
Multivariate Cox-proportional hazards models were used to determine independent
predictors of mortality.
Results: 682 patients (67%) had STEMI and 342 patients (33%) had NSTEMI. DES
were used in 39% of patients with greater use in NSTEMI (37% vs. 42%, p¼0.043),
but length of stented segments were similar between both groups. When adjusting for
patient, clinical and procedural characteristics, the use of DES was an independent
predictor of 1-year mortality (HR¼0.66, 95% CI: 0.51-0.86, p¼0.002). Furthermore,
DES use conferred mortality beneﬁt in STEMI (HR¼0.63, 95% CI: 0.46-0.87,
p¼0.005), but no beneﬁt in NSTEMI (HR¼0.96, 95% CI: 0.57-1.63, p¼0.889).Conclusions: In this large registry analysis of patients with CS treated with PCI, the
use of DES was associated with a signiﬁcant reduction in 1-year mortality. This
beneﬁt appears to be seen speciﬁcally in patients with STEMI.
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Background: The use of second-generation drug-eluting stents (DES) compared with
bare metal stents (BMS) in patients with ST-segment elevation myocardial infarction
(STEMI) reduces the rate of major adverse cardiac events. There is scarce information
about the inﬂuence of gender in the performance of second generation DES in STEMI
patients. The aim of the study is to evaluate the impact of gender on the performance
of everolimus-eluting stent (EES) vs. BMS in STEMI patients at 2-year follow-up.acts/POSTER/STEMI/NSTEMI/ACS B79
